Hospital
Dignity Health
Dignity Health was paid $15.62M by Medicaid between Jan 2018 and Nov 2024, across 136 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoDIGNITY HEALTH
MOUNT SHASTA, CA 96067
MOUNT SHASTA, CA 96067
33aNPI1518085430assigned 03/27/2007
33bProvider typeCritical Access Hospital
28Total paid$15.62M
24GClaims216,504
24DCodes billed136
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#4 of 30
Median peer was paid$3.14M
This provider vs. median5.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,187 | $1.88M | |
| 2019 | 33,003 | $2.11M | |
| 2020 | 30,737 | $2.28M | |
| 2021 | 32,218 | $2.50M | |
| 2022 | 35,033 | $2.73M | |
| 2023 | 36,007 | $2.82M | |
| 2024incomplete | 18,319 | $1.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 21,862 | 18,369 | $3.89M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 16% | 12,561 | 11,001 | $2.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.1% | 13,432 | 3,104 | $1.11M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 3,916 | 3,527 | $652K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.6% | 1,294 | 1,117 | $565K |
| 97750 | 3.4% | 3,295 | 1,683 | $533K | |
| 99201 | 3.4% | 1,875 | 1,180 | $532K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 570 | 559 | $424K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.7% | 1,817 | 616 | $415K |
| 97139 | 2.4% | 7,638 | 1,477 | $369K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.3% | 1,123 | 1,122 | $354K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 2,776 | 2,476 | $344K |
124 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 813 | $316K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 3,136 | $243K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 2,301 | $212K |
| 80053 | Comprehensive metabolic panel | 1.3% | 15,134 | $208K |
| J3490 | Unclassified drugs | 1.1% | 12,777 | $176K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 2,228 | $176K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 1,213 | $160K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,161 | $155K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,725 | $143K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,158 | $138K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,209 | $118K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,026 | $101K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,654 | $101K |
| 80061 | Lipid panel | <1% | 4,635 | $84K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,339 | $79K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,298 | $78K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,730 | $76K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 94 | $73K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 951 | $54K |
| 97010 | <1% | 398 | $54K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,198 | $48K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,191 | $48K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,466 | $48K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,101 | $43K |
| 83605 | <1% | 2,988 | $43K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,860 | $41K |
| 85027 | <1% | 3,154 | $39K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 185 | $38K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,815 | $37K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,853 | $36K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 172 | $31K |
| 84484 | <1% | 2,198 | $30K | |
| 72100 | <1% | 289 | $28K | |
| 83690 | <1% | 3,059 | $27K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,061 | $26K |
| 73030 | <1% | 284 | $26K | |
| 99070 | <1% | 1,598 | $25K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,309 | $24K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 404 | $24K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 477 | $23K |
| 84439 | <1% | 2,038 | $22K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 131 | $21K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 902 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,583 | $19K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 970 | $19K |
| 81001 | <1% | 3,121 | $19K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 82 | $18K |
| 0450 | Emergency room services | <1% | 186 | $18K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,302 | $17K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 783 | $16K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 114 | $16K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 26 | $16K |
| 76830 | Ultrasound, transvaginal | <1% | 78 | $16K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 26 | $14K |
| 87070 | <1% | 1,003 | $14K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 841 | $14K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $13K |
| 86703 | <1% | 429 | $13K | |
| 87631 | <1% | 113 | $12K | |
| 73562 | <1% | 144 | $11K | |
| 87186 | <1% | 722 | $11K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 973 | $11K |
| 85730 | <1% | 1,354 | $11K | |
| 74178 | <1% | 12 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 51 | $10K |
| 85610 | <1% | 1,844 | $10K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 25 | $9K |
| 86803 | <1% | 560 | $9K | |
| 83735 | <1% | 1,224 | $9K | |
| 73610 | <1% | 110 | $8K | |
| 83880 | <1% | 255 | $8K | |
| 73630 | <1% | 96 | $8K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 77 | $7K |
| 87040 | <1% | 340 | $7K | |
| 76641 | <1% | 28 | $6K | |
| 87077 | <1% | 519 | $6K | |
| 81003 | <1% | 1,586 | $6K | |
| 85007 | <1% | 1,148 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 393 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 21 | $4K |
| 87899 | <1% | 351 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 58 | $3K |
| 73130 | <1% | 42 | $3K | |
| 73110 | <1% | 41 | $3K | |
| 85652 | <1% | 704 | $3K | |
| 86850 | <1% | 713 | $3K | |
| 86901 | <1% | 752 | $3K | |
| 86900 | <1% | 740 | $2K | |
| 82746 | <1% | 126 | $2K | |
| 86592 | <1% | 545 | $2K | |
| 82962 | <1% | 420 | $2K | |
| 82550 | <1% | 101 | $2K | |
| 87205 | <1% | 197 | $2K | |
| 86141 | <1% | 66 | $2K | |
| 86780 | <1% | 96 | $1K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $1K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 128 | $1K |
| S0028 | Injection, famotidine, 20 mg | <1% | 234 | $1K |
| 82607 | <1% | 39 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 34 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 155 | $1K |
| Z7502 | <1% | 28 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 67 | $991.96 |
| 80076 | <1% | 39 | $892.32 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 64 | $852.51 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 101 | $844.87 |
| 83540 | <1% | 123 | $676.13 | |
| 73140 | <1% | 12 | $659.78 | |
| 12001 | <1% | 12 | $568.08 | |
| 86769 | <1% | 13 | $547.69 | |
| 86140 | <1% | 128 | $542.80 | |
| 83550 | <1% | 67 | $435.57 | |
| 87653 | <1% | 14 | $427.28 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 63 | $421.22 |
| 85379 | <1% | 50 | $380.91 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 12 | $312.08 |
| 82274 | <1% | 16 | $228.64 | |
| 87340 | <1% | 24 | $225.26 | |
| 84153 | <1% | 13 | $179.85 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 28 | $139.65 |
| 82728 | <1% | 12 | $132.77 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 14 | $110.46 |
| 84100 | <1% | 14 | $63.15 | |
| 84703 | <1% | 12 | $21.50 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.